Inactivation of CDKN2A gene (p16) in gallbladder carcinoma;Inactivación del gen CDKN2A (p16) en cáncer de la vesícula biliar

Revista Medica de Chile

Volumn 132, Issue 11, 2004, Pages 1369-1376

  Roa S, Juan Carlos ^a,c   Vo, Quynh ^b   Araya O, Juan Carlos ^a   Villaseca H, Miguel ^a   Guzmán G, Pablo ^a   Ibacache S, Gilda ^a   De Aretxabala U, Xabier ^a   Roa E, Iván ^a  

^a UNIVERSIDAD DE LA FRONTERA   (Chile)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSIDAD DE LA FRONTERA   (Chile)

Author keywords

Gallbladder neoplasms; Genes, CDKN2; Genes, p16; Immunohistochemistry

Indexed keywords

GENE PRODUCT; PROTEIN P16;

ADENOCARCINOMA; ADULT; ALLELIC IMBALANCE; ARTICLE; CANCER GENETICS; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE INHIBITOR 2A GENE; DNA METHYLATION; FEMALE; GALLBLADDER CARCINOMA; GENE; GENE EXPRESSION; GENE INACTIVATION; GENETIC ASSOCIATION; GENETIC STABILITY; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE MARKER; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION;

ADULT; ALLELIC IMBALANCE; CARCINOMA; CHI-SQUARE DISTRIBUTION; DNA METHYLATION; FEMALE; GALLBLADDER NEOPLASMS; GENE SILENCING; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE REPEATS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS);

EID: 17444400986     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. MEDINA E, KAEMPFFER AM. Mortalidad del adulto en Chile. Rev Méd Chile 2000; 128: 1144-9.
2. MEDINA E, KAEMPFFER AM. Mortalidad por cáncer en Chile. Consideraciones epidemiológicas. Rev Méd Chile 2001; 129: 1195-202.
3. MEDINA E, KAEMPFFER AM, IRARRÁZAVAL M, DE CROIZET VA, TOPOROWICZ M. Aspectos epidemiológicos de enfermedades de la vesícula biliar en Chile. Bol Oficina Sanit Panam 1976; 80: 220-8.
4. ROA I, ARAYA JC, ARETXABALA X, SALINAS C, WISTUBA I. Enfermedades de la vesícula biliar en el área de Temuco. Rev Méd Chile 1989; 118: 889-94.
5. SHERR CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60: 3689-95.
6. PALMERO I, PETERS G. Perturbation of cell cycle regulators in human cancer. Cancer Surv 1996; 27: 351-67.
7. SCHAFER KA. The cell cycle: a review. Vet Pathol 1998; 35: 461-78.
8. HRUBAN RH, IACOBUZIO-DONAHUE C, WILENTZ RE, GOGGINS M, KERN SE. Molecular pathology of pancreatic cancer. Cancer J 2001; 7: 251-8.
9. LIGGETT WH JR, SIDRANSKY D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998; 16: 1197-206.
10. The new TNM classification in gastroenterology (1997). Endoscopy 1998; 30: 643-9.
11. BURTON MP, SCHNEIDER BG, BROWN R, ESCAMILLA-PONCE N, GULLEY ML. Comparison of histologic stains for use in PCR analysis of microdissected, paraffin-embedded tissues. Biotechniques 1998; 24: 86-92.
12. SCHNEIDER BG, PULITZER DR, BROWN RD, PRIHODA TJ, BOSTWICK DG, SALDÍVAR V ET AL. Allelic imbalance in gastric cancer: an affected site on chromosome arm 3p. Genes Chromosomes Cancer 1995; 13: 263-71.
13. BOLAND CR, THIBODEAU SN, HAMILTON SR, SIDRANSKY D, ESHLEMAN JR, BURT RW ET AL. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57.
14. HERMAN JG, GRAFF JR, MYOHANEN S, NELKIN BD, BAYLIN SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-6.
15. HERMAN JG, MERLO A, MAO L, LAPIDUS RG, ISSA JP, DAVIDSON NE ET AL. Inactivation of the CDKN2/pl6/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-30.
16. ROA JC, VILLASECA MA, ROA I, ARAYA JC, OKAYASU I, FLORES P ET AL. Expresión inmunohistoquímica de la oncoproteína p53 en adenomas y adenocarcinomas del intestino grueso. Rev Méd Chile 1997; 125: 523-9.
17. GERADTS J, HRUBAN RH, SCHUTTE M, KERN SE, MAYNARD R. Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies. Appl Immunohistochem Mol Morphol 2000; 8: 71-9.
18. Rocco JW, SIDRANSKY D. p16 (MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001; 264: 42-55.
19. PIEPKORN M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol 2000; 42: 705-22; 723-6.
20. ROBERTSON KD, JONES PA. DNA methylation: past, present and future directions. Carcinogenesis 2000; 21: 461-7.
21. WAJED SA, LAIRD PW, DEMEESTER TR. DNA methylation: an alternative pathway to cancer. Ann Surg 2001; 234: 10-20.
22. ESTELLER M, SILVA JM, DOMÍNGUEZ G, BONILLA F, MATIAS-GUIU X, LERMA E ET AL. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-9.
23. KANE MF, LODA M, GAIDA GM, LIPMAN J, MISHRA R, GOLDMAN H ET AL. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57: 808-11.
24. KAMB A, SHATTUCK-EIDENS D, EELES R, LIU Q, GRUIS NA, DING W ET AL. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994; 8: 23-6.
25. SCHUTTE M, HRUBAN RH, GERADTS J, MAYNARD R, HILGERS W, RABINDRAN SK ET AL. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126-30.
26. YOSHIDA S, TODOROKI T, ICHIKAWA Y, HANAI S, SUZUKI H, HORI M ET AL. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 1995; 55: 2756-60.
27. CACA K, FEISTHAMMEL J, KLEE K, TANNAPFEL A, WITZIGMANN H, WITTEKIND C ET AL. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Int J Cancer 2002; 97: 481-8.
28. KIM YT, KIM J, JANG YH, LEE WJ, RYU JK, PARK YK ET AL. Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett 2001; 169: 59-68.
29. UEKI T, HSING AW, GAO YT, WANG BS, SHEN MC, CHENG J ET AL. Alterations of p16 and prognosis in biliary tract cancers from a population-based study in China. Clin Cancer Res 2004; 10: 1717-25.
30. HOUSE MG, WISTUBA, II, ARGANI P, GUO M, SCHULICK RD, HRUBAN RH ET AL. Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. Ann Surg Oncol 2003; 10: 882-9.
31. SHI YZ, HUI AM, LI X, TAKAYAMA T, MAKUUCHI M. Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16INK4 protein in gallbladder carcinomas. Clin Cancer Res 2000; 6: 4096-100.
32. SOLIMAN AS, BONDY ML, EL-BADAWY SA, MOKHTAR N, EISSA S, BAYOUMY S ET AL. Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. Br J Cancer 2001; 85: 1037-46.
33. MCCREDIE M. Cancer epidemiology in migrant populations. Recent Results Cancer Res 1998; 154: 298-305.
34. DONG M, NIO Y, TAMURA K, SONG MM, GUO KJ, GUO RX ET AL. Ki-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese, and Western patients. Cancer Epidemiol Biomarkers Prev 2000; 9: 279-84.
35. THOMAS HV, REEVES GK, KEY TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997; 8: 922-8.
36. ROA I, ARAYA JC, WISTUBA I, VILLASECA M, DE ARETXABALA X, BURGOS L. Cancer de la vesicula biliar en la IX región de Chile. Impacto del estudio anatomopatológico de 474 casos. Rev Méd Chile 1994; 122: 1248-56.
37. CHEN Z, Ko A, YANG J, JORDAN VC. Methylation of CpG island is not a ubiquitous mechanism for the loss of oestrogen receptor in breast cancer cells. Br J Cancer 1998; 77: 181-5.
38. ADAMS JB. Enzymatic regulation of estradiol-17 beta concentrations in human breast cancer cells. Breast Cancer Res Treat 1992; 20: 145-54.
39. MARUYAMA R, TOYOOKA S, TOYOOKA KO, VIRMANI AK, ZOCHBAUER-MULLER S, FARINAS AJ ET AL. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002; 8: 514-9.
40. QUAN ZW, WU K, WANGJ, SHI W, ZHANG Z, MERRELL RC. Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg 2001; 193: 380-3.
41. ESTELLER M, GONZALEZ S, RISQUES RA, MARCUELLO E, MANGUES R, GERMA JR ET AL. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19: 299-304.